Brainsway (NASDAQ:BWAY – Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.
Valuation and Earnings
This table compares Brainsway and Green Thumb Industries”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Brainsway | $52.22 million | 10.84 | $7.57 million | $0.44 | 32.05 |
| Green Thumb Industries | $1.18 billion | 1.29 | $114.15 million | $0.54 | 14.32 |
Risk and Volatility
Brainsway has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Green Thumb Industries has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Brainsway and Green Thumb Industries, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Brainsway | 0 | 2 | 5 | 0 | 2.71 |
| Green Thumb Industries | 0 | 1 | 1 | 1 | 3.00 |
Brainsway presently has a consensus target price of $16.95, suggesting a potential upside of 20.20%. Green Thumb Industries has a consensus target price of $18.00, suggesting a potential upside of 132.71%. Given Green Thumb Industries’ stronger consensus rating and higher probable upside, analysts plainly believe Green Thumb Industries is more favorable than Brainsway.
Institutional & Insider Ownership
30.1% of Brainsway shares are owned by institutional investors. Comparatively, 0.1% of Green Thumb Industries shares are owned by institutional investors. 19.0% of Brainsway shares are owned by insiders. Comparatively, 9.4% of Green Thumb Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Brainsway and Green Thumb Industries’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Brainsway | 15.65% | 12.74% | 8.17% |
| Green Thumb Industries | 10.48% | 6.03% | 4.09% |
Summary
Brainsway beats Green Thumb Industries on 8 of the 15 factors compared between the two stocks.
About Brainsway
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
About Green Thumb Industries
Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.
